Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2020-08, Vol.112 (2), p.264-264 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 264 |
|---|---|
| container_issue | 2 |
| container_start_page | 264 |
| container_title | International journal of hematology |
| container_volume | 112 |
| creator | Lucijanic, Marko Krecak, Ivan |
| description | |
| doi_str_mv | 10.1007/s12185-020-02915-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000539704200002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2426710683</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-3a0e38b53f640cf5b5c4e2396cdf445422025c757e1db214c6ffcefbf175d853</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhS0EokPhBVggSyxR4NqO42SJRuVHqsSm-8hxrmfcJvZgO0LzKn1anKaUHWJhXS--c3x9DiFvGXxkAOpTYpy1sgIO5XRMVt0zsmNtIyuhVP2c7KDjspKKwQV5ldItAFNQq5fkQnDJOqb4jtxfWYsm02CpPiDVfqQmzCEObnTZYaLB03xEOqKZnMeVO0xhxrhMOlLrphx1dgUqA6nz1Bxj8M7Q-YxTcCOdcLnD2Wl6Khz6nOjokgk-O784f6D5HENane-c12m1OLrB5RDTa_LC6inhm8d5SW6-XN3sv1XXP75-33--royQkCuhAUU7SGGbGoyVgzQ1ctE1ZrR1LWvOgUujpEI2DpzVprHWoB0sU3Jspbgk7zfbUww_F0y5vw1L9OXFnte8Kek1rSgU3yhT1k0RbX-Kbtbx3DPo1zb6rY2-tNE_tNF3RfTu0XoZZhyfJH_iL8CHDfiFQ7DJlIAMPmEAIEVXKuPlBivd_j-9d_mhmH1YfC5SsUlTwf0B499P_mP_3wTRuao</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2426710683</pqid></control><display><type>article</type><title>Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors</title><source>MEDLINE</source><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Lucijanic, Marko ; Krecak, Ivan</creator><creatorcontrib>Lucijanic, Marko ; Krecak, Ivan</creatorcontrib><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-020-02915-9</identifier><identifier>PMID: 32519172</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Age Factors ; Cardiovascular Diseases - epidemiology ; Chronic myeloid leukemia ; Comorbidity ; Diabetes Mellitus - epidemiology ; Female ; Glomerular filtration rate ; Glomerular Filtration Rate - drug effects ; Hematology ; Humans ; Imatinib Mesylate - adverse effects ; Kinases ; Letter to the Editor ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology ; Life Sciences & Biomedicine ; Male ; Medicine ; Medicine & Public Health ; Myeloid leukemia ; Oncology ; Protein Kinase Inhibitors - adverse effects ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Pyrimidines - adverse effects ; Science & Technology ; Tyrosine ; Tyrosine kinase inhibitors ; Withholding Treatment</subject><ispartof>International journal of hematology, 2020-08, Vol.112 (2), p.264-264</ispartof><rights>Japanese Society of Hematology 2020</rights><rights>Japanese Society of Hematology 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>0</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000539704200002</woscitedreferencesoriginalsourcerecordid><cites>FETCH-LOGICAL-c350t-3a0e38b53f640cf5b5c4e2396cdf445422025c757e1db214c6ffcefbf175d853</cites><orcidid>0000-0002-8642-305X ; 0000-0002-1372-2040</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-020-02915-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-020-02915-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,782,786,27933,27934,28257,41497,42566,51328</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32519172$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lucijanic, Marko</creatorcontrib><creatorcontrib>Krecak, Ivan</creatorcontrib><title>Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>INT J HEMATOL</addtitle><addtitle>Int J Hematol</addtitle><subject>Age Factors</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Chronic myeloid leukemia</subject><subject>Comorbidity</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Female</subject><subject>Glomerular filtration rate</subject><subject>Glomerular Filtration Rate - drug effects</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate - adverse effects</subject><subject>Kinases</subject><subject>Letter to the Editor</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Myeloid leukemia</subject><subject>Oncology</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Pyrimidines - adverse effects</subject><subject>Science & Technology</subject><subject>Tyrosine</subject><subject>Tyrosine kinase inhibitors</subject><subject>Withholding Treatment</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkc1u1DAUhS0EokPhBVggSyxR4NqO42SJRuVHqsSm-8hxrmfcJvZgO0LzKn1anKaUHWJhXS--c3x9DiFvGXxkAOpTYpy1sgIO5XRMVt0zsmNtIyuhVP2c7KDjspKKwQV5ldItAFNQq5fkQnDJOqb4jtxfWYsm02CpPiDVfqQmzCEObnTZYaLB03xEOqKZnMeVO0xhxrhMOlLrphx1dgUqA6nz1Bxj8M7Q-YxTcCOdcLnD2Wl6Khz6nOjokgk-O784f6D5HENane-c12m1OLrB5RDTa_LC6inhm8d5SW6-XN3sv1XXP75-33--royQkCuhAUU7SGGbGoyVgzQ1ctE1ZrR1LWvOgUujpEI2DpzVprHWoB0sU3Jspbgk7zfbUww_F0y5vw1L9OXFnte8Kek1rSgU3yhT1k0RbX-Kbtbx3DPo1zb6rY2-tNE_tNF3RfTu0XoZZhyfJH_iL8CHDfiFQ7DJlIAMPmEAIEVXKuPlBivd_j-9d_mhmH1YfC5SsUlTwf0B499P_mP_3wTRuao</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Lucijanic, Marko</creator><creator>Krecak, Ivan</creator><general>Springer Singapore</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-8642-305X</orcidid><orcidid>https://orcid.org/0000-0002-1372-2040</orcidid></search><sort><creationdate>20200801</creationdate><title>Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors</title><author>Lucijanic, Marko ; Krecak, Ivan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-3a0e38b53f640cf5b5c4e2396cdf445422025c757e1db214c6ffcefbf175d853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age Factors</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Chronic myeloid leukemia</topic><topic>Comorbidity</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Female</topic><topic>Glomerular filtration rate</topic><topic>Glomerular Filtration Rate - drug effects</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate - adverse effects</topic><topic>Kinases</topic><topic>Letter to the Editor</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Myeloid leukemia</topic><topic>Oncology</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Pyrimidines - adverse effects</topic><topic>Science & Technology</topic><topic>Tyrosine</topic><topic>Tyrosine kinase inhibitors</topic><topic>Withholding Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lucijanic, Marko</creatorcontrib><creatorcontrib>Krecak, Ivan</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lucijanic, Marko</au><au>Krecak, Ivan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><stitle>INT J HEMATOL</stitle><addtitle>Int J Hematol</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>112</volume><issue>2</issue><spage>264</spage><epage>264</epage><pages>264-264</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>32519172</pmid><doi>10.1007/s12185-020-02915-9</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8642-305X</orcidid><orcidid>https://orcid.org/0000-0002-1372-2040</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2020-08, Vol.112 (2), p.264-264 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_webofscience_primary_000539704200002 |
| source | MEDLINE; SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Age Factors Cardiovascular Diseases - epidemiology Chronic myeloid leukemia Comorbidity Diabetes Mellitus - epidemiology Female Glomerular filtration rate Glomerular Filtration Rate - drug effects Hematology Humans Imatinib Mesylate - adverse effects Kinases Letter to the Editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology Life Sciences & Biomedicine Male Medicine Medicine & Public Health Myeloid leukemia Oncology Protein Kinase Inhibitors - adverse effects Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - adverse effects Science & Technology Tyrosine Tyrosine kinase inhibitors Withholding Treatment |
| title | Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T08%3A41%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20age%20and%20comorbidities%20on%20the%20decline%20of%20glomerular%20filtration%20rate%20in%20chronic%20myeloid%20leukemia%20patients%20discontinuing%20tyrosine%20kinase%20inhibitors&rft.jtitle=International%20journal%20of%20hematology&rft.au=Lucijanic,%20Marko&rft.date=2020-08-01&rft.volume=112&rft.issue=2&rft.spage=264&rft.epage=264&rft.pages=264-264&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-020-02915-9&rft_dat=%3Cproquest_webof%3E2426710683%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2426710683&rft_id=info:pmid/32519172&rfr_iscdi=true |